# Moderna's Genocidal Juggernaut

> Moderna's cancer cure stock faces criticism as insider selling intensifies.
- Title: Moderna's Genocidal Juggernaut · TradingView | Shortify
- Summary: Moderna's cancer cure stock faces criticism as insider selling intensifies. Moderna's stock is criticized for being a 'genocidal juggernaut' with no cash…
- Keywords: moderna, nasdaq, mrna, insider selling, cancer cure, stock market, business, finance, Moderna's, Genocidal, Juggernaut, TradingView
- Source: TradingView — https://tradingview.com/chart/MRNA/iHBLJzOm-10-20-26-mrna-genocidal-juggernaut
- Published: 2026-10-22T19:03:16+00:00
- Read time: 1 min
- Topics: moderna, nasdaq, mrna, insider selling, cancer cure, stock market, business, finance
## Moderna's Stock Status
Moderna's stock trades at 35x next year's sales but grows 15% annually.
## Insider Selling Trend
Tens of millions in insider selling observed with no recent insider buys.
## Cancer Cure Claims
Moderna claims to cure cancer but made money only during the global pandemic.
## Key takeaway

Moderna's stock is criticized for being a 'genocidal juggernaut' with no cash flows despite high growth expectations.